Monoclonal and Polyclonal Antibodies Research

LICHEN generates light-chain antibody sequences conditioned on heavy chains and experimental needs, producing valid, diverse, and functional sequences.

This paper develops a cell-free protein synthesis method combined with FCS to rapidly produce and characterize antibody fragments, showing improved solubility and binding analysis.

This study develops and characterizes AVA, single-domain protein binders that neutralize major household allergens from cats, dogs, and dust mites.

This study develops sweeping antibodies against IL-16, showing improved antigen clearance compared to conventional antibodies.

This paper computationally designs and experimentally validates a single-domain antibody that specifically recognizes a WT1 peptide-loaded class I MHC complex with high affinity and specificity.

This paper introduces a supramolecular self-assembly method for site-specific antibody conjugation using coiled-coil peptides, demonstrating improved uniformity and efficacy in targeting HER2+ tumors.

This study develops a functional screening method to identify TCR-like antibodies targeting tumor neoantigens, demonstrating their anti-tumor efficacy in vitro and in vivo.

The paper reports cryo-EM structures of chimeric and human IgM, revealing structural insights into JC-free pIgM assembly and demonstrating antigen-targeting potential for disease prevention.

This paper introduces Chai-2, a model that designs antibodies with a 16% hit rate, achieving success in 50% of targets without prior binders, and enables rapid validation in under two weeks.

The paper describes a method to isolate sIgA1 from nasal secretions using jacalin-conjugated beads, confirming its identity via Western blotting and highlighting its potential as a biomarker for nasal vaccine evaluation.

GLIMPSE-1, a protein language model trained on human antibody sequences, improves antibody engineering for affinity, cross-reactivity, and developability by leveraging patterns in the human repertoire.

This study shows that genetic variations in immunoglobulin light chain loci influence the diversity of expressed light chain antibodies, affecting amino acid sequences and gene usage.

The paper computationally designs monomeric Fc variants with distinct pH-responsive FcRn-binding profiles, showing enhanced binding at acidic pH and weak binding at neutral pH.

This paper predicts pharmacokinetic profiles of monoclonal antibodies using sequence-based machine learning and compartmental modeling, achieving accurate predictions with reduced reliance on animal testing.

This paper develops a synthetic nanobody library for radiopharmaceutical ligand discovery, demonstrating its utility through PET imaging of a calreticulin-binding nanobody.

AbBFN2 is a generative antibody foundation model that unifies diverse data sources and enables flexible conditional generation for multiple antibody design tasks.

This paper demonstrates that HER2-VEGFA bispecific antibodies induce co-phagocytosis of VEGFA and HER2-overexpressing cancer cells, enhancing antitumor responses in preclinical models.

This study develops and characterizes six nanobodies as potential therapeutics for PH1 by targeting misfolded AGT variants, showing high affinity and functional enhancement in cellular models.

The paper identifies ITGA3B1 as a therapeutic target for metastatic bladder cancer using a phenotypic screening strategy and develops an ADC targeting this integrin complex, showing antitumor efficacy in preclinical models.

The paper maps the affinity and allostery in human IgG antibody Fc region-Fc γ receptor interactions by analyzing amino acid variations and their effects on binding and effector functions.

The paper introduces an LC-MS method to analyze IgG4 repertoires with clonal resolution, revealing high diversity and persistence of IgG4 molecules in serum over time.

This paper evaluates the antitumor efficacy of humanized 16A antibody conjugates with DNA topoisomerase I inhibitors, showing potent in vitro and in vivo activity against MUC1-expressing tumors.

The paper develops a sensitive GLP-compliant ELISA for detecting GP101 diabody in mouse serum, achieving 15pg/mL sensitivity.

This paper isolates and characterizes two high-affinity nanobodies against EGFR, showing their potent anti-tumor activity in vitro.

The paper presents a rapid method to develop anti-infective biologicals effective against drug-resistant bacteria and yeasts using antibody-drug conjugates with dual modes of action.

This study designs antibodies without prior information across eight targets, achieving high precision, sensitivity, and specificity, validated by Cryo-EM and comparable to commercial antibodies.

This study uses AI to humanize a murine antibody by grafting only essential paratopes, reducing immunogenicity while preserving efficacy and developability.

The paper identifies clonotype-enriched mutations in the light chain of a public antibody that enhance affinity for a conserved viral epitope and increase after repeated vaccinations.

This study validates secondary nanobodies for multiplexed immunoassays and provides optimized protocols for their use.